Condition: Prostate Cancer · Sponsor: Amgen
The overall aim of the trial is to evaluate the safety, tolerability, and pharmacokinetics (PK) of AMG 509 (monotherapy and in combination with abiraterone acetate and enzalutamide) and to evaluate preliminary efficacy. As of Protocol Amendment 10 (09 July 2025), only Parts 4A expansion, 6, and 7 are open to accrual.
This description comes directly from the study's public registry record.
Amgen Call Center · 866-572-6436 · medinfo@amgen.com
Always discuss trial participation with your own doctor first.
| City of Hope National Medical Center | Duarte, California, United States | Recruiting |
| Providence Saint Jude Medical Center | Fullerton, California, United States | Recruiting |
| University of California San Francisco | San Francisco, California, United States | Recruiting |
| Rocky Mountain Cancer Centers | Aurora, Colorado, United States | Recruiting |
| Yale New Haven Hospital | New Haven, Connecticut, United States | Recruiting |
| Emory University | Atlanta, Georgia, United States | Recruiting |
| Indiana University | Indianapolis, Indiana, United States | Recruiting |
| MidAmerica Cancer Care | Merriam, Kansas, United States | Recruiting |
| Tulane Medical Center | New Orleans, Louisiana, United States | Completed |
| Washington University | St Louis, Missouri, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Duke University Medical Center | Durham, North Carolina, United States | Recruiting |
+ 45 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04221542